Influence of inoculation site of combined oil-adjuvanted vaccine on the antibody response in chickens

Identification of Novel Linear Epitopes Located in the Infectious Bronchitis Virus Spike S2 Region

We identified novel linear epitopes on the infectious bronchitis virus (IBV) spike S2 region. The conformational structure of the IBV spike protein was predicted from a homologous protein, human coronavirus NL63 spike. Although the obtained structure was incomplete, most of the IBV spike protein structure was predicted; the N-terminus of the S1 region could not be predicted due to its variability. In the model, the region located in the proximity of the fusion peptide appeared to be well conserved, and we evaluated the antigenicity of these domains, which are involved in the membrane fusion machinery. Western blotting revealed that IBV TM86 spike residues 686-723 were antigenic. Epitope mapping analysis using synthesized peptides revealed that IBV TM86 spike 669-685 (SNFSTGAFNISLLLTPP), 686-697 (SNPRGRSFIEDL), and 692-703 (SFIEDLLFTSVE) residues were major linear epitopes; two identified epitopes (686-697 and 692-703) were covered by the fusion peptide, and the other epitope (669-685) was adjacent to the fusion peptide. Although the identified epitopes are identically located as the neutralizing epitope in severe acute respiratory syndrome coronavirus, the recombinant protein that includes those epitopes could not elicit neutralizing antibodies against IBV. This is the first report describing IBV spike S2 epitopes located in the proximity of the fusion peptide, and it is suggested that the spike fusion machinery of IBV may differ from that of severe acute respiratory syndrome coronavirus, or, alternatively, IBV may have another mechanism to penetrate the cell membrane.

Decreased neutralizing antigenicity in IBV S1 protein expressed from mammalian cells

•

The recombinant infectious bronchitis virus (IBV) S1 protein was highly glycosylated and many complex N-glycans were attached on the surface.

•

The recombinant S1 protein elicited antibodies against IBV S1 protein, but most of the antibodies could not neutralize IBV.

•

The results indicated that the recombinant S1 may not be able to display neutralizing epitopes by losing native conformation or masking by glycan.

We evaluated the antigenicity of recombinant infectious bronchitis virus (IBV) S1 protein expressed in mammalian cells. Recombinant S1 was expressed as a secreted protein fused with a trimerization motif peptide, then purified using Ni Sepharose. The purified protein was analyzed by Western blotting, mixed with oil adjuvant, and administered to 29-day-old specific-pathogen-free chickens. Six weeks after immunization, anti-IBV neutralizing titer and anti-S1 ELISA titer were determined; immunized chickens then were inoculated with IBV via the trachea and ciliary activity was observed. Results showed that the recombinant S1 protein was highly glycosylated, and the neutralizing antigenicity of recombinant S1 protein was lower than that of inactivated virus. However, anti-S1 ELISA indicated that the recombinant S1 protein induced antibodies against S1. These results suggest that the recombinant S1 may retain non-neutralizing epitopes but have unnatural glycosylation pattern and conformation, resulting in lacking neutralizing conformational epitopes. In conclusion, the neutralizing antigenicity of recombinant S1 protein expressed from mammalian cells was decreased, and was not sufficient to induce neutralizing antibodies.

Effect of liquid paraffin on antibody responses and local adverse reactions of bivalent oil adjuvanted vaccines containing newcastle disease virus and infectious bronchitis virus

Effects of liquid paraffin on antibody responses and local adverse reactions after intramuscular injection of oil adjuvanted vaccines containing Newcastle disease (ND) and infectious bronchitis (IB) virus were investigated in chickens. Each vaccine was prepared with a liquid paraffin such as Carnation, Crystol 52 and Lytol. These vaccines induced sustained antibody responses against ND and IB. Among local adverse reactions, Lytol induced granulomatous reactions and abscesses, but Carnation and Crystol 52 did not. The residual weight of liquid paraffin at the injection site decreased in the order Carnation, Crystol 52, Lytol. Crystol 52 was composed of relatively few short-chain hydrocarbons (i.e., <n-C16H34) and long-chain hydrocarbons (i.e., >n-C20H42). The vaccine with liquid paraffin mainly composed of n-C16H34-n-C20H42 was suggested to induce fewer adverse reactions.

Immunity, vaccination and the avian intestinal tract

Defence of the intestinal mucosal surface from enteric pathogens is initially mediated by secretory IgA (SIgA). As oral immunization of non-replicating antigen induces minimal SIgA antibody titers, novel immunization strategies which selectively induce mucosal immune responses in mammals are now being assessed in chickens. The strategies reviewed include the route of antigen delivery, the incorporation of antigenic components in delivery vehicles, the inclusion of immunomodulators in the vaccine formula or in the diet, and manipulation of intestinal microflora. The differences in anatomical organization and immunological mechanisms between birds and mammals must be considered when manipulating avian intestinal immunity with the latest immunotechnologies developed for mammals. Our knowledge of the function and functioning of the avian mucosal system is discussed. Progress in our understanding of this system, the location of precursor IgA B cells and antigen sampling by these sites is not as advanced as knowledge of the mammalian system, highlighting the need for ongoing research into the avian application of novel vaccination strategies.